We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.
- Recent RVNC Stock Price: $13.15
- Yearly Gain for RVNC stock: -46.91%
- Market Cap for RVNC stock: $1.47B
- P/E Ratio for RVNC stock: -3.044
Will RVNC's stock price go up? Is there an accurate RVNC stock forecast available?
TipRanks.com reports that Revance Therapeutics currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $38.60. The target pricing ranges from a high RVNC forecast of $44 down to a low forecast of $33. Revance Therapeutics (RVNC)’s last closing stock price was $13.15 which would put the average price target at 159.64% upside.
In addition, TradingView issued a Strong sell rating for RVNC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RVNC stock.
Other analysts covering RVNC include:
- Douglas Tsao of H.C. Wainwright issued a Buy rating with the price target of $41 on 21 hours ago
- Serge Belanger of Needham issued a Buy rating with the price target of $35 on 21 hours ago
- David Amsellem of Piper Sandler issued a Buy rating with the price target of $44 on 21 hours ago
- Balaji Prasad of Barclays issued a Buy rating with the price target of $40 on 1 day ago
If you are wondering if RVNC is a good stock to buy, here are 3rd party ratings for RVNC stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 39% (97 out of 246)
What is the sentiment on the street regarding Revance Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for RVNC stock: Neutral
- Blogger Consensus for RVNC stock: Neutral
- Media Buzz for RVNC stock: Very Low
- Insider Signal for RVNC stock: ―
- Investor Sentiment for RVNC stock: Very Positive
- Hedge Fund signal for RVNC stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on RVNC stock including scouring the social networks like RVNC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RVNC stock chart >>
Summary: Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
- Recent TSHA Stock Price: $3.06
- Yearly Gain for TSHA stock: 30.40%
- Market Cap for TSHA stock: $199.84M
- P/E Ratio for TSHA stock: -1.422
Will TSHA's stock price go up? Is there an accurate TSHA stock forecast available?
TipRanks.com reports that Taysha Gene Therapies currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $5.20. The target pricing ranges from a high TSHA forecast of $7 down to a low forecast of $4. Taysha Gene Therapies (TSHA)’s last closing stock price was $3.06 which would put the average price target at 85.29% upside.
In addition, TradingView issued a buy rating for TSHA stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on TSHA stock.
Other analysts covering TSHA include:
- Silvan Tuerkcan of JMP Securities issued a Buy rating with the price target of $4 on 21 hours ago
- Geulah Livshits of Chardan Capital issued a Buy rating with the price target of $4 on 1 day ago
- Joon Lee of Truist Financial issued a Buy rating with the price target of $5 on 1 day ago
- Kristen Kluska of Cantor Fitzgerald issued a Buy rating with the price target of $7 on 1 month ago
If you are wondering if TSHA is a good stock to buy, here are 3rd party ratings for TSHA stock:
- TipRanks.com: Strong Buy
- TradingView.com: buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 35% (86 out of 246)
What is the sentiment on the street regarding Taysha Gene Therapies? (Current ratings compiled by TipRanks.com)
- News Sentiment for TSHA stock: Very Bullish
- Blogger Consensus for TSHA stock: Bullish
- Media Buzz for TSHA stock: Medium
- Insider Signal for TSHA stock: Positive
- Investor Sentiment for TSHA stock: Positive
- Hedge Fund signal for TSHA stock: Neutral
The stock market is extremely volatile, and you need to do your own research on TSHA stock including scouring the social networks like TSHA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TSHA stock chart >>
Summary: Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.
- Recent MRNS Stock Price: $7.20
- Yearly Gain for MRNS stock: 0.43%
- Market Cap for MRNS stock: $296.58M
- P/E Ratio for MRNS stock: -46.247
Will MRNS's stock price go up? Is there an accurate MRNS stock forecast available?
TipRanks.com reports that Marinus currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.00. The target pricing ranges from a high MRNS forecast of $32 down to a low forecast of $15. Marinus (MRNS)’s last closing stock price was $7.20 which would put the average price target at 191.87% upside.
In addition, TradingView issued a buy rating for MRNS stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRNS stock.
Other analysts covering MRNS include:
- Michael Higgins of Ladenburg Thalmann & Co. issued a Buy rating with the price target of $15 on 21 hours ago
- Jason Butler of JMP Securities issued a Buy rating with the price target of $15 on 21 hours ago
- Brian Abrahams of RBC Capital issued a Buy rating with the price target of $21 on 1 day ago
- Joon Lee of Truist Financial issued a Buy rating with the price target of $32 on 1 month ago
If you are wondering if MRNS is a good stock to buy, here are 3rd party ratings for MRNS stock:
- TipRanks.com: Strong Buy
- TradingView.com: buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 43% (105 out of 246)
What is the sentiment on the street regarding Marinus? (Current ratings compiled by TipRanks.com)
- News Sentiment for MRNS stock: Very Bullish
- Blogger Consensus for MRNS stock: ―
- Media Buzz for MRNS stock: Very High
- Insider Signal for MRNS stock: ―
- Investor Sentiment for MRNS stock: Very Negative
- Hedge Fund signal for MRNS stock: Negative
The stock market is extremely volatile, and you need to do your own research on MRNS stock including scouring the social networks like MRNS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MRNS stock chart >>
Summary: Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.
- Recent BSX Stock Price: $54.10
- Yearly Gain for BSX stock: 31.16%
- Market Cap for BSX stock: $77.60B
- P/E Ratio for BSX stock: 89.141
Will BSX's stock price go up? Is there an accurate BSX stock forecast available?
TipRanks.com reports that Boston Scientific currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $61.00. The target pricing ranges from a high BSX forecast of $64 down to a low forecast of $58. Boston Scientific (BSX)’s last closing stock price was $54.10 which would put the average price target at 11.70% upside.
In addition, TradingView issued a Strong buy rating for BSX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BSX stock.
Other analysts covering BSX include:
- Shagun Singh Chadha of RBC Capital issued a Buy rating with the price target of $58 on 21 hours ago
- Travis Steed of Bank of America Securities issued a Buy rating with the price target of $60 on 1 day ago
- Marie Thibault of BTIG issued a Buy rating with the price target of $62 on 1 day ago
- Kristen Stewart of C.L. King issued a Buy rating with the price target of $64 on 1 week ago
If you are wondering if BSX is a good stock to buy, here are 3rd party ratings for BSX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 30% (74 out of 246)
What is the sentiment on the street regarding Boston Scientific? (Current ratings compiled by TipRanks.com)
- News Sentiment for BSX stock: Very Bullish
- Blogger Consensus for BSX stock: Bullish
- Media Buzz for BSX stock: Low
- Insider Signal for BSX stock: ―
- Investor Sentiment for BSX stock: Very Positive
- Hedge Fund signal for BSX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on BSX stock including scouring the social networks like BSX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BSX stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
